Optimizing regional therapy for melanoma

Annals of Surgical Oncology

Volumn 16, Issue 5, 2009, Pages 1095-1097

  Beasley, Georgia M ^a   Tyler, Douglas S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTHIONINE SULFOXIMINE; CREATINE KINASE; DACTINOMYCIN; MELPHALAN; SORAFENIB;

ACIDOSIS; AMPUTATION; CANCER COMBINATION CHEMOTHERAPY; CATHETER; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPOXIA; INFUSION; ISOLATED LIMB INFUSION; LIMB TOXICITY; MELANOMA; MORBIDITY; REVIEW; TOXICITY; TREATMENT RESPONSE;

CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; HUMANS; HYPERTHERMIA, INDUCED; MELANOMA; SKIN NEOPLASMS;

EID: 64249112078     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-009-0329-4     Document Type: Review

References (15)

1. Kroon HM, Moncrieff M, Kam PCA, et al. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients. Ann Surg Oncol. 2009:16 (in press).
2. JF Thompson RC Waugh RPM Saw PCA Kam 1994 Isolated limb infusion with melphalan for recurrent limb melanoma: A simple alternative to isolated limb perfusion Reg Cancer Treat 7 188 192
3. HM Kroon M Moncrieff PCA Kam 2008 Outcomes following isolated limb infusion for melanoma. A 14-year experience Ann Surg Oncol 15 11 3003 3013 epub 2008 May 29
4. WR Cornett LM McCall RP Petersen MI Ross HA Briele RD Noyes 2006 Prospective randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone versus melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020 J Clin Oncol 24 4196 4201
5. Beasley GM, Petersen RP, McMahon NS, Mosca PJ, Zager JS, Hochwald SN, et al. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the United States. J Am Coll Surg. 2008 (accepted).
6. MS Brady K Brown A Patel C Fisher W Marx 2006 A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity Ann Surg Oncol 13 8 1123 1129
7. P Lindner A Doubrovsky PCA Kam JF Thompson 2002 Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma Ann Surg Oncol 9 127 136
8. FK Storm DL Morton 1985 Value of therapeutic hyperthermic limb perfusion in advanced recurrent melanoma of the lower extremity Am J Surg 15 32 35
9. Koops HS, Lejeune KJ, Kroon BBR, Hoekstra HJ. Isolated limb perfusion for melanoma: technical aspects. In: Thompson JF, Morton DL, Kroon BBR, editors. Textbook of melanoma. London: Martin Dunitz; 2004. p. 404-9.
10. BC Vrouenraets GA Hart AM Eggermont JM Klaase BN van Geel OE Nieweg 1999 Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma J Am Coll Surg 188 522 530
11. GM Beasley RP Petersen JS Yoo T Aloia W Petros G Sanders 2008 Isolated limb infusion for in-transit malignant melanoma of the extremity: a well tolerated but less effective alternative to hyperthermic isolated limb perfusion Ann Surg Oncol 15 8 2195 2205 epub 2008 June
12. JF Thompson PCA Kam I Ramzan DF Yau 1995 Clinical pharmacokinetics of melphalan during isolated limb perfusion: compartmental modeling and moment analysis Reg Cancer Treat 8 83 87
13. T-Y Cheng E Grubbs O Abdul-Wahab SY Leu CF Hung W Petros 2003 Marked variability of melphalan plasma drug levels during regional hyperthermic isolated limb perfusion Am J Surg 186 5 460 467
14. McMahon N, Cheng TY, Beasley GM, et al. Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity? Ann Surg Oncol. 2008 (accepted).
15. Beasley GM, McMahon N, Sanders G, et al. A phase I/II study of systemic ADH-1 in combination with isolated limb infusion with melphalan in patients with locally advanced in-transit melanoma. American Society of Clinical Oncology (ASCO) 44th annual meeting. May 30-June 3, 2008. Chicago, IL.